Episode 98: Evidence-Based Medicine in a COVID World

Adam Cifu Headshot

Episode 98: Evidence-Based Medicine in a COVID World

Adam Cifu, MD, general internist and professor of medicine at the University of Chicago, is fresh off his rounds and ready to talk about the advantages and pitfalls of evidence-based medicine in today’s medical world. Dr. Cifu offers his thoughts on the level of evidence needed for vaccinations in children as well as the number of vaccinations and boosters needed for adults, what the evidence tells us about long COVID, whether mask wearing on planes and various other locations still carries any weight, and a general commentary on how evidence factors (or doesn’t) into Twitter discussions surrounding medicine.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More